releases: https://www.sanders.senate.gov/newsroom/press-releases/sanders-statement-on-new-373000-cancer-therapy
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://www.sanders.senate.gov/newsroom/press-releases/sanders-statement-on-new-373000-cancer-therapy | Sanders Statement on New $373,000 Cancer Therapy | 2017-10-19 | 2017 | 2017-10 | Independent | House | VT | Bernard Sanders | S000033 | www.sanders.senate.gov | legacy | Sanders Statement on New $373,000 Cancer Therapy Thursday, October 19, 2017 WASHINGTON, Oct. 19 – Sen. Bernie Sanders (I-Vt.) issued the following statement Thursday after the pharmaceutical company Gilead said the list price for the cancer drug Yescarta would be $373,000: “Gilead, one of the greediest pharmaceutical corporations in the world, is once again gouging Americans dealing with a life-threatening illness. This time, Gilead plans to charge an outrageous $373,000 per patient for a life-saving cancer drug developed with taxpayer money. What good does a breakthrough medication do if no one can afford it? No one in America should die because they cannot afford the cost of the medication they need, yet that is exactly what will happen if we continue to allow Gilead and other pharmaceutical corporations to charge whatever price they want. “The pharmaceutical industry’s greed must end. It’s time for Congress and President Trump – who has spoken often about drug makers ‘getting away with murder’ – to take action to lower the cost of prescription drugs in America.” | 1 | 2026-03-30T12:14:52Z | 2026-03-30T12:14:52Z |